Certara, Inc. (CERT)

Certara, Inc. is trading at $8.23, down 1.44% on the session. The 50 day average sits at $7.34 and the 200 day at $7.23, which puts the stock in a uptrend. RSI is at 58.5, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $7.88 with resistance near $8.39, so that band frames the current range. Average daily movement is roughly $0.35, or about 4.3% of the share price, which is what any stop placement has to allow for. The overall health score of 75 out of 100 combines a trend score of 100, momentum of 58 and a risk score of 58.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.